William Koopal
Physician Assistant · Albany, GANPI 1184190837
Payments from drug & device makers
Across 80 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$519
- Otsuka America Pharmaceutical, Inc.$79
- Lilly USA, LLC$78
- Johnson & Johnson$76
- Vanda Pharmaceuticals Inc.$61
- Dexcom, Inc.$55
- plus $389 from 16 others
What the payments were for
- Food & beverage$1,258100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 39 | $519 |
| Otsuka America Pharmaceutical, Inc. | 4 | $79 |
| Lilly USA, LLC | 5 | $78 |
| Johnson & Johnson | 4 | $76 |
| Vanda Pharmaceuticals Inc. | 3 | $61 |
| Dexcom, Inc. | 3 | $55 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $54 |
| Novo Nordisk | 3 | $52 |
| Alkermes, Inc. | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Amgen | 1 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Masimo Corporation | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Athena Bioscience, LLC | 1 | $17 |
| Pfizer | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| GSK | 1 | $14 |
| AstraZeneca | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$1,258 in reported general payments places this provider in the 70th percentile of 3,581 physician assistant providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 32 | $56,768 |
| Invega SustennaPaliperidone Palmitate | 13 | $46,542 |
| OzempicSemaglutide | 37 | $37,424 |
| MounjaroTirzepatide | 13 | $13,435 |
| JanuviaSitagliptin Phosphate | 12 | $8,946 |
| Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm | 16 | $1,429 |
| Trazodone Hcl | 103 | $1,184 |
| Fluphenazine Hcl | 13 | $1,121 |
| Mirtazapine | 69 | $828 |
| Quetiapine Fumarate | 59 | $816 |
| Gabapentin | 47 | $779 |
| Buspirone Hcl | 38 | $559 |
| Hydroxyzine Hcl | 46 | $471 |
| Haloperidol | 11 | $444 |
| Bupropion XlBupropion Hcl | 28 | $390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $519 | $56,76832 claims |
| Johnson & JohnsonInvega Sustenna | $76 | $46,54213 claims |
| Novo NordiskOzempic | $52 | $37,42437 claims |
| Lilly USA, LLCMounjaro | $78 | $13,43513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,581 physician assistant providers in Georgia.
Other physician assistant in Albany
- Kevin BushAlbany$14K
- Christopher BassAlbany$13K
- Douglas DiruggieroCartersville$1.3M
- Jennifer CobbsAtlanta$1M
- A BrunnerStockbridge$1M
- Joseph LangshawCalhoun$887K
- Alison MoeAtlanta$410K
- Maggie SchreckAtlanta$389K
- Lisa HillMarietta$190K
- Laura BishopBrunswick$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.